Asker Healthcare Group AB (SE:ASKER)
:ASKER
Top Page
Asker Healthcare Group AB
(ASKER)
Select Model
Select Model
Rating:54Neutral
Price Target:
kr66.00
▼(-19.76% Downside)
Action:DowngradedDate:02/18/26
The score is mainly supported by strong growth and improving operating fundamentals with positive free cash flow, but is pulled down by a pronounced technical downtrend/weak momentum and a high P/E valuation alongside thin net margins and remaining leverage risk.
Positive Factors
Strong revenue growth trend
Sustained, accelerating top-line growth (38.61% in 2025) reflects expanding market penetration and demand for medical products. For a distributor of recurring consumables, this durable revenue expansion supports scale benefits, stronger supplier leverage, and longer-term contract opportunities.
Negative Factors
Thin and volatile net margins
A low net margin (~2.9%) leaves little buffer against cost inflation, pricing pressure, or adverse one-off items. For a distribution business with variable procurement and financing costs, thin net margins raise the risk that earnings swings will materially affect free cash and capital allocation over the medium term.
Read all positive and negative factors
Positive Factors
Negative Factors
Strong revenue growth trend
Sustained, accelerating top-line growth (38.61% in 2025) reflects expanding market penetration and demand for medical products. For a distributor of recurring consumables, this durable revenue expansion supports scale benefits, stronger supplier leverage, and longer-term contract opportunities.
Read all positive factors
Asker Healthcare Group AB (ASKER) vs. iShares MSCI Sweden ETF (EWD)
Market Cap
kr25.88B
Dividend YieldN/A
Average Volume (3M)1.96M
Price to Earnings (P/E)63.2
Beta (1Y)0.59
Revenue GrowthN/A
EPS GrowthN/A
CountrySE
Employees4,238
SectorHealthcare
Sector Strength45
IndustryMedical - Care Facilities
Share Statistics
EPS (TTM)0.67
Shares Outstanding383,036,500
10 Day Avg. Volume378,678
30 Day Avg. Volume1,960,693
Financial Highlights & Ratios
PEG Ratio1.92
Price to Book (P/B)4.74
Price to Sales (P/S)1.85
P/FCF Ratio42.11
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)2.73
Revenue Forecast (FY)kr18.89B
Asker Healthcare Group AB Business Overview & Revenue Model
Company Description
Asker Healthcare Group AB provides medical supplies, devices, and equipment, and related solutions that support patient care. It offers protective products, infusion products, and dressings; measuring instruments for diabetes and blood pressure; a...
How the Company Makes Money
ASKER generates revenue through multiple streams, primarily by selling its pharmaceutical products and medical devices to healthcare providers, hospitals, and pharmacies. The company employs a direct sales model as well as partnerships with distri...
Asker Healthcare Group AB Financial Statement Overview
Summary
Income Statement
68
Positive
Balance Sheet
56
Neutral
Cash Flow
60
Neutral
| Breakdown | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 16.79B | 15.03B | 13.45B | 11.72B | 9.35B |
| Gross Profit | 6.87B | 5.88B | 4.52B | 3.78B | 2.61B |
| EBITDA | 1.23B | 1.47B | 1.12B | 1.12B | 670.00M |
| Net Income | 492.00M | 360.00M | 203.00M | 430.00M | 467.00M |
Balance Sheet | |||||
| Total Assets | 16.77B | 13.12B | 11.33B | 10.23B | 7.36B |
| Cash, Cash Equivalents and Short-Term Investments | 884.00M | 490.00M | 391.00M | 211.00M | 494.00M |
| Total Debt | 5.81B | 5.96B | 4.97B | 4.74B | 3.93B |
| Total Liabilities | 10.19B | 9.62B | 8.29B | 7.44B | 5.54B |
| Stockholders Equity | 6.55B | 3.47B | 3.02B | 2.76B | 1.79B |
Cash Flow | |||||
| Free Cash Flow | 738.00M | 879.00M | 901.00M | 853.00M | 258.00M |
| Operating Cash Flow | 1.33B | 1.23B | 1.05B | 976.00M | 382.00M |
| Investing Cash Flow | -2.91B | -1.46B | -783.00M | -1.86B | -843.00M |
| Financing Cash Flow | 2.02B | 305.00M | -83.00M | 572.00M | 619.00M |
Asker Healthcare Group AB Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
61 Neutral | kr16.68B | 18.64 | 7.24% | 0.46% | 5.14% | 236.75% | |
56 Neutral | kr28.26B | 39.46 | ― | 0.66% | 13.89% | 231.42% | |
54 Neutral | kr25.88B | 63.17 | ― | ― | ― | ― | |
54 Neutral | kr21.22B | 546.38 | 3.08% | 4.25% | -0.90% | -70.95% | |
54 Neutral | kr6.97B | 26.11 | 4.40% | 3.01% | -0.05% | -13.44% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
49 Neutral | kr12.58B | -0.87 | 3.34% | 0.80% | -1.29% | ― |
* Healthcare Sector Average
SE:ASKER
Asker Healthcare Group AB
67.57
-14.43
-17.60%
SE:EKTA.B
Elekta AB
55.55
4.09
7.94%
SE:VITR
Vitrolife AB
92.85
-71.64
-43.55%
SE:MCOV.B
Medicover AB
187.20
-5.04
-2.62%
SE:ALIF.B
AddLife AB
136.80
-9.91
-6.76%
SE:ARJO.B
Arjo AB
25.58
-10.45
-29.00%
Asker Healthcare Group AB Corporate Events
Asker Healthcare Delivers Strong 2025 on M&A-Driven Growth and Margin Gains
Feb 10, 2026
Asker Healthcare Group reported a strong 2025, with net sales rising 12% to SEK 16.8bn and adjusted EBITA up 17%, lifting the margin to 9.5% for the year and 10% in the fourth quarter. Profit and earnings per share grew sharply, cash flow from ope...
Asker Healthcare Reshapes Leadership in M&A and ESG to Support Growth Agenda
Feb 4, 2026
Asker Healthcare Group has reshuffled its senior leadership, appointing current MA Director Lovisa Hedin as Head of MA and promoting Head of HR Kerstin Mjömark to Head of HR and ESG, effective 1 April, while current MA chief Ola Nordh and ESG...
Asker Healthcare Group Sets Date for 2025 Year-End Report and Webcast
Jan 27, 2026
Asker Healthcare Group will release its Year-End Report for 2025 on 10 February at 08:10 CET and will host a webcast presentation the same day at 10:00 CET for investors, analysts and media. CEO Johan Falk and CFO Thomas Moss will present and comm...
Asker Healthcare Group to Boost German Homecare Presence with GHC/MPF Acquisition
Jan 7, 2026
Asker Healthcare Group has agreed to acquire 100% of German Healthcare GmbH and Medicalprodukte Vertrieb Flensburg GmbH, two interlinked German homecare-focused medical supplies businesses specialising in incontinence and urology products. The tar...
Asker Healthcare Group Acquires Van Heek Medical to Strengthen Benelux Presence
Dec 16, 2025
Asker Healthcare Group has announced the acquisition of Van Heek Medical, a prominent manufacturer and distributor of medical supplies in the Benelux region. This strategic move is expected to enhance Asker’s presence in the region and contr...
Asker Healthcare Group Announces Board Changes at Extraordinary General Meeting
Dec 9, 2025
At the Extraordinary General Meeting of Asker Healthcare Group AB held on December 9, 2025, the board resolved to maintain its composition of six members and approved the payment of board and committee fees to all members until the next Annual Gen...
Asker Healthcare Group Acquires French Cardiology Distributor Cardio Dépôt
Dec 2, 2025
Asker Healthcare Group has acquired Cardio Dépôt, a French distributor specializing in cardiology medical devices and consumables. This acquisition is expected to enhance Asker’s product offerings and digital presence in the cardio...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.